Introduction
============

Endometriosis is a chronic, estrogen-dependent inflammatory, heritable, common gynecological condition by growth of endometrial tissue in sites other than the uterine cavity, most commonly in the pelvic cavity, including the ovaries, the uterosacral ligaments, and pouch of Douglas ([@b1-mmr-16-05-5881]). Endometriosis affects up to 10% of reproductive-aged women ([@b2-mmr-16-05-5881]), but with varying symptoms, delayed diagnosis and misdiagnosis, the true prevalence of endometriosis is unknown. Susceptibility to endometriosis is known to be influenced by genetic factors ([@b3-mmr-16-05-5881]--[@b7-mmr-16-05-5881]), with heritability to have been estimated at approximately 50% from twin studies ([@b8-mmr-16-05-5881],[@b9-mmr-16-05-5881]). A strong familial aggregation has also been reported in a large pedigree of non-human primates ([@b10-mmr-16-05-5881]).

Multiple factors are thought to be involved in the development of endometriosis including genetic and environmental ones, although the exact genomic basis of endometriosis is not yet clear and the exact etiopathogenic mechanism of endometriosis remains to be determined. Currently, the most accepted theory seems to be Sampson\'s retrograde menstruation hypothesis, which suggests that during menstruation, endometrial fragments migrate through fallopian tubes and reach the peritoneum, as they are able to attach, survive, and implant at different locations ([@b11-mmr-16-05-5881]).

Numerous candidate genes are involved initially in the pathogenesis of endometriosis, including genes involved in inflammation, cell cycle regulation, growth factors, hormone receptors and adhesion molecules ([@b12-mmr-16-05-5881]). However, results from those studies have conflicting results and absence of replication in independent populations. Genome-wide association studies (GWAS) and meta-analyses have led to the identification of disease-risk loci that alter a woman\'s risk of developing the disorder and provide new insights into potential pathways leading to endometriosis. At present, 19 independent single nucleotide polymorphisms (SNPs) have been robustly associated with endometriosis explaining 5.19% of the disease variance ([@b13-mmr-16-05-5881]). Of note, the number of these loci is increasing as the proportion of cases analyzed are limited to more severe disease stages (stage III/IV endometriosis) rather than stage I/II, thus indicating that moderate to severe endometriosis cases have greater genetic burden relative to minimal or mild disease ([@b14-mmr-16-05-5881],[@b15-mmr-16-05-5881]). All the identified genome-wide significant loci are located in either intronic (non-coding) regions of genes or intergenic regions. The roles of these variants in the regulation of the expression of target genes has yet to be identified ([@b16-mmr-16-05-5881]). A meta-analysis based on GWAS as well as replication datasets ([@b14-mmr-16-05-5881]) provided evidence for the genome-wide significant association of six loci including rs7521902 (near *WNT4*) and rs10859871 (near *VEZT*). These results were confirmed by a recent meta-analysis conducted by Sapkota *et al*, which, additionally, identified rs11031006 of the *FSHB* gene as a novel endometriosis-associated SNP ([@b13-mmr-16-05-5881]).

It is known that there are population differences for endometriosis in terms of genetic susceptibility and disease manifestations. Thus, genetic studies reported that some specific genotypes are associated with endometriosis in selective populations, such as Brazil, Turkey and Taiwan ([@b17-mmr-16-05-5881]--[@b20-mmr-16-05-5881]). Accumulating evidence indicates that ethnic heterogeneity of genetic risk factors exists for various complex disorders in Greece such as systemic lupus erythematosus (SLE) ([@b21-mmr-16-05-5881],[@b22-mmr-16-05-5881]), juvenile idiopathic arthritis (JIA) ([@b23-mmr-16-05-5881]), and rheumatoid arthritis (RA) ([@b24-mmr-16-05-5881],[@b25-mmr-16-05-5881]). Therefore, ethnic-specific association studies provide novel evidence that can confirm previously reported genetic associations in different populations or question their direct associative role.

The aim of the present study was to identify an association of rs7521902 SNP located 21 kb downstream of wingless-type MMTV integration site family member 4 (*WNT4*), *VEZT* rs10859871 SNP located 17 kb upstream of the *VEZT* gene and *FSHB* rs11031006 SNP located in the 5′ region of *FSHB* with overall endometriosis as well as with the severe stages (ASRM III--IV) of this condition in a Greek population.

Patients and methods
====================

### Patient population and study design

In this case control association study, 316 women were enrolled (166 endometriosis patients and 150 controls) followed in the Department of Obstetrics and Gynecology of Venizeleion Hospital of Heraklion (Heraklion, Greece). The average age of the Greek endometriosis and control cohorts was 32.25±7.1 and 29.49±6.7 years, respectively. The women with endometriosis were diagnosed surgically (laparotomy or laparoscopy), and the disease was confirmed histologically from biopsies. Staging of the disease was performed according to the revised American Fertility Society classification ([@b26-mmr-16-05-5881]). All the members of the control group had given birth to 2--5 (2.3±0.6) children and had no previous medical record of chronic pelvic pain, dysmenorrhea, or dyspareunia. Both cases and controls were unrelated, living in the same urban environment and came from the same Greek population. All the subjects were of self-reported Greek origin. The study was performed in the Section of Molecular Pathology and Human Genetics of the Medical School of Crete, after obtaining the approval of the Research Committee of the Venizeleion Hospital of Heraklion and was carried out in compliance with the declaration of Helsinki for Medical Research involving human subjects.

### Genotyping

Whole blood was collected preoperatively in ethylenediaminetetraacetic acid (EDTA)-containing tubes. Genomic DNA was isolated from peripheral blood leukocytes by using the commercial kit (PureLink^®^ Genomic DNA Mini kit; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. The extracted DNA was stored at −20°C until analyzed. Allelic discrimination of *WNT4* rs7521902, *VEZT* rs10859871 and *FSHB* rs11031006 SNPs was carried out using pre-made TaqMan SNP Genotyping assays from Applied Biosystems (Foster City, CA, USA), according to the Applied Biosystems protocol (cat. nos. C_30192951_10, C_30917499_10 and C_32036787_10 for rs7521902, rs10859871 and rs11031006, respectively). A 96-well plate was prepared with a mixture on an Applied Biosystems ViiA™ 7 Real-Time PCR system of 1X TaqMan SNP Genotyping assay, 1X TaqMan Universal Master mix (both from Applied Biosystems) and 20 ng DNA per well. The PCR conditions were denaturation at 95°C for 10 min, followed by 40 cycles of 95°C denaturation for 15 sec and a 60°C annealing for 1 min. After PCR, the plates were read, and the data analysed using Quant Studio™ Real-Time PCR Software (Applied Biosystems). Allelic discrimination plots were all reviewed individually for quality. Each assay was run with negative controls. For quality control, a random 10% of the samples were amplified twice to ensure accuracy of the results, with the reproducibility rate being 100%. The genotyping success for all the SNPs analyzed was \>98%.

### Statistical analysis

The cases and controls used in the analysis were unrelated. Statistical analysis was performed with the GraphPad Prism statistical program (GraphPad Software, San Diego, CA, USA), by applying the additive model. The Chi-square (χ^2^) test, with one or two degrees of freedom or Fisher\'s exact test was used to examine differences of genotype and allele frequencies between patients and controls, where all the SNPs had a call rate of \>98%. A two tailed P\<0.05 was defined as statistically significant. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. The genetic variants under investigation were evaluated for deviation from Hardy-Weinberg equilibrium (HWE) by comparing observed and expected genotype frequencies by means of the χ^2^ test or Fisher\'s exact test in the control groups (using the program named 'Calculate'; Copyright TRG, SR, INMD, 2008). The distribution of genotypes in the case group for all the three SNPs examined were found to be under HWE (P\>0.01).

Results
=======

### The rs7521902 WNT4 SNP

The patients with endometriosis did not present any increase in genotypic or allelic frequencies compared with the controls (P=0.36, OR=0.52, 95% CI, 0.16--1.71 and P=0.16, OR=1.37, 95% CI, 0.89--2.11 for AA and A, respectively) ([Table I](#tI-mmr-16-05-5881){ref-type="table"}), apart from previous findings in other ethnic populations, which reported allele A of rs7521902 as a risk allele for endometriosis ([@b27-mmr-16-05-5881]). However, when patients were analyzed according to the severity of the disease, a significant association was detected regarding the AC genotype of rs7521902 in patients with stage III/IV of the disease (P=0.0359, OR=1.96, 95% CI, 1.06--3.59) ([Table II](#tII-mmr-16-05-5881){ref-type="table"}).

### The rs10859871 VEZT SNP

In the case of *VEZT* rs10859871 SNP, a statistical significant difference was found in the frequency of AC genotype in patients and controls (P=0.01, OR=0.39, 95% CI, 0.19--0.81) ([Table III](#tIII-mmr-16-05-5881){ref-type="table"}). Additionally, irrespective of the small sample size, in an analysis conducted on endometriosis stage, evidence for association with the endometriosis cases stratified uniquely to stages I or III was found for the same (AC) genotype of the rs10859871 (P=0.0024, OR=0.20, 95% CI, 0.07--0.55 and P=0.049, OR=0.31, 95% CI, 0.1--0.91, respectively) (data not shown). We did not find evidence for a significant difference between endometriosis patients stages III/IV and controls for genotype or allele frequencies of rs10859871 (P=0.16, OR=0.51, 95% CI, 0.29--1.28 and P=0.26, OR=0.79, 95% CI, 0.54--1.17 for the AA genotype and A allele, respectively) ([Table IV](#tIV-mmr-16-05-5881){ref-type="table"}).

### The rs11031006 FSHB SNP

Genotype and allele frequencies of the *FSHB* rs11031006 SNP in women with endometriosis and controls are shown in [Table V](#tV-mmr-16-05-5881){ref-type="table"}. The results showed a decreased frequency of the GA genotype in patients with endometriosis compared with controls (P=0.0438, OR=0.55, 95% CI, 0.31--0.98), while this difference was also evident for the minor allele A (P=0.0316, OR=0.55, 95% CI, 0.32--0.95). No association between this SNP and endometriosis was revealed after an analysis conducted according to stages III/IV of the disease (P=0.5, OR=0.76, 95% CI, 0.39--1.50 and P=0.44, OR=0.74, 95% CI, 0.39--1.40 for GA genotype and allele A, respectively) ([Table VI](#tVI-mmr-16-05-5881){ref-type="table"}).

Discussion
==========

Although GWAS have detected many endometriosis susceptibility genes, it is clear that there are differences in genetic associations with endometriosis across different world populations ([@b14-mmr-16-05-5881]). Therefore, it is important to study the genetic basis of this condition in multiple populations and replicate previous findings, which would be crucial for some genome-wide significant endometriosis risk variants such as rs1859871 in *VEZT*, rs11031006 in *FSHB* genetic loci or rs7521902 *WNT4*. The rs 7521902 was previously shown to yield contradictory results according to ethnic populations analyzed ([@b31-mmr-16-05-5881]). In this study, it was found that AC genotype of rs7521902 SNP is associated with an increased risk for endometriosis in patients of stages III/IV only.

rs7521902 *WNT4* SNP has been repeatedly associated with an increased susceptibility for endometriosis in women of different ethnicities, including British, Australian, Italian, and Japanese women ([@b14-mmr-16-05-5881],[@b27-mmr-16-05-5881]--[@b30-mmr-16-05-5881]). In the present study, no association was detected between the risk allele C of this SNP and increased risk for endometriosis. These data are consistent with those reported previously by Sundqvist *et al* and Mafra *et al* ([@b31-mmr-16-05-5881],[@b32-mmr-16-05-5881]). In particular, no association was observed between the rs7521902 SNP and women of European ancestry, 1,129 with and 831 without endometriosis, analyzed in Belgium ([@b31-mmr-16-05-5881]). Similarly, no association was detected either in a study conducted in 800 Brazilian women (400 with and 400 without endometriosis) ([@b32-mmr-16-05-5881]), or in another one performed in Chinese Han women 646 with and 766 without endometriosis ([@b33-mmr-16-05-5881]). Although this inability of some of the aforementioned studies to confirm previous findings may result from type II errors and may be related to sample size (as stated by the authors), the discrepancy may also be due in some cases to the investigating populations being collected from different endometriosis staging, and more likely, to the variations among ethnicities. However, in the analysis conducted on the Greek patients according to the stage of endometriosis, a genotypic association was detected.

The rs7521902 is an intergenic variant located at 1p36.12 ([@b34-mmr-16-05-5881]). *WNT4* encodes for a protein imperative for development of the female reproductive tract, representing a critical, well-known regulator of uterine development ([@b35-mmr-16-05-5881]). In addition, *WNT4* has been shown to be expressed in normal peritoneum, suggesting that endometriosis can arise through metaplasia using developmental pathways involved in the development of the female reproductive tract ([@b36-mmr-16-05-5881]). Based on these biological functions, *WNT4* has been indicated as a strong candidate for the development of functional changes involved in the endometriosis, considering that *WNT4* is expressed in human endometrium during both the proliferative and secretory phases ([@b37-mmr-16-05-5881]). Variants at the 1p36 chromosomal region, involving the *WNT4* gene, may contribute to endometriosis for susceptibility through abnormal cell growth in the female genital tract ([@b32-mmr-16-05-5881]).

The rs10859871 is located in the chromosome 12q22 region, 17 kb upstream of the *VEZT* gene ([@b14-mmr-16-05-5881]). VEZT is a transmembrane protein with a short extracellular and long intracellular domain, which anchors to myosin VIIA as part of the adherent junctional complex in epithelial cells ([@b38-mmr-16-05-5881],[@b39-mmr-16-05-5881]). In blood and endometrium, the endometriosis risk allele C of rs10859871 SNP has been associated with an increase in *VEZT* expression and this aberrant expression of *VEZT* may be involved in the pathogenesis of endometriosis. Notably, in the present study the allelic effect was in the opposite direction compared to the original GWAS ([@b40-mmr-16-05-5881]).

An association between rs11031006 and endometriosis was detected in the present study. This SNP lies in the 5′ region of *FSHB* (chr 11p14.1), which is involved in sex steroid hormone pathways. FSHB encodes the hormone-specific b-subunit of follicle stimulating hormone (FSH), a key promoter of ovarian follicle growth and oestrogen production. Based on data from the ENCODE project ([@b41-mmr-16-05-5881]), it was found that this SNP alters the sequence of 11 protein-binding motifs including that of the estrogen receptor α, thus indicating a possible effect on hormonal feedback inhibition. Recently, allele G of this SNP has been reported to be significantly associated with higher serum FSH levels ([@b42-mmr-16-05-5881]).

As the pathogenesis of endometriosis is highly complex, involving both genetic background and environmental conditions, conflicting studies in several cases have made the interpretation of these data challenging. A definite advantage of our study was the attention paid to the selection of a homogeneous patient cohort and control group. As a consequence, the results are unlikely to be biased by sampling. The major weakness of our study that must be considered when interpreting our results was small sample size due to the lack of a non-invasive method to confirm a diagnosis of endometriosis at the population level. Failure to confirm previous findings is largely attributed to insufficient power, population differences as well as to interaction with genetic and/or non-genetic factors ([@b43-mmr-16-05-5881]). Of note, an important benefit of analyzing genetic associations for different ethnic populations is that it also can shed light on the breakdown of associations due to population differences in linkage disequilibrium. At the genomic level, this 'trans-ethnic fine mapping' is an important method to narrow down the signal towards a causal variant. However, this is less likely to be useful in populations that are similar in common disease variant distributions such as the Greek vs. other European ancestry populations. Further exploration of the loci by assaying surrounding variants, such as through GWAS, is required to test this aspect.

In conclusion, the results from this study demonstrate the necessity of GWAS in larger sample sizes to reveal and/or confirm genetic variants associated with endometriosis in the Greek population. Our data emphasize the importance of assessing genetic variants in different populations, even within Europe, in an attempt to define the genetic architecture of endometriosis and the magnitude of the effects of specific risk alleles in different populations. Functional studies are required to elucidate the exact contribution of the variants analyzed in endometriosis risk.
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###### 

Genotype and allele frequencies of the *WNT4* rs7521902 polymorphism analyzed in 166 women with endometriosis and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls       P-value   OR (95% CI)
  ------------------- --------------- -------------- --------- -------------------
  Genotypes           N=166           N=150                    
    CC                111 (66.87%)    113 (75.33%)             1.00 (Reference)
    AC                49 (29.52%)     30 (20.00%)    0.066     1.66 (0.98--2.80)
    AA                6 (3.61%)       7 (4.67%)      0.36      0.52 (0.16--1.71)
  Alleles             N=332           N=300                    
    C                 271 (81.63%)    256 (85.33%)             1.00 (Reference)
    A                 61 (18.37%)     44 (14.67%)    0.16      1.37 (0.89--2.11)

OR, odds ratio; CI, confidence interval.

###### 

Genotype and allele frequencies of the *WNT4* rs7521902 polymorphism analyzed in 79 women with endometriosis (stage III and IV) and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls      P-value      OR (95% CI)
  ------------------- --------------- ------------- ------------ -------------------
  Genotypes           N=79            N=150                      
    CC                50 (63.3%)      113 (75.3%)                1.00 (Reference)
    AC                26 (32,0%)      30 (20.0%)    **0.0359**   1.96 (1.06--3.59)
    AA                3 (3.8%)        7 (4.7%)      0.49         0.96 (0.24--3.90)
  Alleles             N=158           N=300                      
    C                 126 (79.8%)     256 (85.3%)                1.00 (Reference)
    A                 32 (20.3%)      44 (14.7%)    0.11         1.55 (0.93--2.57)

OR, odds ratio; CI, confidence interval. Bold, statistically significant difference.

###### 

Genotype and allele frequencies of the *VEZT* rs10859871 polymorphism analyzed in 166 women with endometriosis and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls      P-value    OR (95% CI)
  ------------------- --------------- ------------- ---------- -------------------
  Genotypes           N=166           N=150                    
    AA                60 (36.1%)      53 (35.3%)    0.07       0.49 (0.23--1.04)
    AC                76 (45.8%)      84 (56.0%)    **0.01**   0.39 (0.19--0.81)
    CC                30 (18.1%)      13 (8.7%)                1.00 (Reference)
  Alleles             N=332           N=300                    
    A                 196 (59.0%)     190 (63.3%)   0.25       0.82 (0.6--1.13)
    C                 136 (41.0%)     110 (36.7%)              1.00 (Reference)

OR, odds ratio; CI, confidence interval. Bold, statistically significant difference

###### 

Genotype and allele frequencies of the *VEZT* rs10859871 polymorphism analyzed in 79 women with endometriosis (stage III and IV) and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls       P-value   OR (95% CI)
  ------------------- --------------- -------------- --------- -------------------
  Genotypes           N=79            N=150                    
    AA                25 (31.65%)     53 (35.33%)    0.16      0.51 (0.29--1.28)
    AC                42 (53.16%)     84 (56%)       0.18      0.54 (0.23--1.29)
    CC                12 (5.19%)      13 (8.67%)               1.00 (Reference)
  Alleles             N=158           N=300                    
    A                 92 (58.23%)     190 (63.33%)   0.26      0.79 (0.54--1.17)
    C                 66 (41.77%)     110 (36.67%)             1.00 (Reference)

OR, odds ratio; CI, confidence interval.

###### 

Genotype and allele frequencies of the *FSHB* rs11031006 polymorphism analyzed in 166 women with endometriosis and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls       P-value      OR (95% CI)
  ------------------- --------------- -------------- ------------ -------------------
  Genotypes           N=79            N=150                       
    GG                142 (85.54%)    114 (76.00%)                1.00 (Reference)
    GA                24 (14.46%)     35 (23.33%)    **0.0438**   0.55 (0.31--0.98)
    AA                0 (0%)          1 (0.67%)      0.4475       0.27 (0.01--6.64)
  Alleles             N=332           N=300                       
    G                 308 (92.77%)    263 (87.67%)                1.00 (Reference)
    A                 24 (7.23%)      37 (12.33%)    **0.0316**   0.55 (0.32--0.95)

OR, odds ratio; CI, confidence interval. Bold, statistically significant difference.

###### 

Genotype and allele frequencies of the *FSHB* rs11031006 polymorphism analyzed in 79 women with endometriosis (stage III and IV) and 150 healthy controls.

  Genotypes/Alleles   Endometriosis   Controls       P-value   OR (95% CI)
  ------------------- --------------- -------------- --------- --------------------
  Genotypes           N=79            N=150                    
    GG                64 (81.01%)     114 (76%)                1.00 (Reference)
    GA                15 (18.99%)     35 (23.33%)    0.5       0.76 (0.39--1.50)
    AA                0 (0%)          1 (0.67%)      1.00      0.59 (0.02--14.71)
  Alleles             N=158           N=300                    
    G                 143 (90.51%)    263 (87.67%)             1.00 (Reference)
    A                 15 (9.49%)      37 (12.33%)    0.44      0.74 (0.39--1.40)

OR, odds ratio; CI, confidence interval.
